Hidradenitis Suppurativa

Below is a list of our hidradenitis suppurativa studies that are currently enrolling. 

A study to test whether an investigational drug helps people with a skin disease called hidradenitis suppurativa

  • Population: Patients aged eighteen years and older
  • Study Condition: Moderate to severe hidradenitis suppurativa

     

  • Study Design:This is a research study to evaluate the efficacy and safety of an investigational drug compared to placebo in the treatment of moderate to severe hidradenitis suppurativa. This study will last up to 70 weeks with 33 clinic visits. After signing the informed consent, trial participants will enter the screening period for up to 28 days, and if all eligibility criteria are met, trial participants will be randomized in a 1:1:1:1 ratio to either active group, including different doses of investigational drug, 1 group gets placebo. Once randomized, trial participants will start a treatment period of 50 weeks. There will be a safety follow up visit 16 weeks after the last dose.

 

 

Please contact Dr. Veronica Emmerich for more information regarding ongoing hidradenitis suppurativa studies. 

Email: emmerich@musc.edu

Phone: (843) 876-0110